The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.

Company Guidance

During the Q3 2025 Novo Nordisk Earnings Conference Call, the company reported impressive financial metrics for the first nine months of 2025, including a 15% sales growth and a 10% operating profit growth. They updated their guidance, narrowing the sales growth range to 8% to 11% and operating profit growth to 4% to 7%, citing lower expectations for their GLP-1 treatments in diabetes and obesity. Novo Nordisk also highlighted strategic initiatives, such as the approval of Rybelsus in the U.S. and EU based on the SOUL trial, and the submission of Mim8 for regulatory approval in rare diseases. The company emphasized their commitment to core areas like diabetes and obesity, expecting significant long-term volume opportunities. They also announced a company-wide transformation to reallocate resources, expecting about DKK 8 billion in annual savings by the end of 2026, with a reduction of approximately 9,000 positions globally.

Strong Sales and Profit Growth

Novo Nordisk achieved a 15% sales growth and a 10% operating profit growth for the first 9 months of 2025.

Expansion in Obesity Care

Obesity care sales increased by 41%, with significant growth in international operations by 83%.

Launch of Wegovy Pill

Novo Nordisk is preparing for the launch of the Wegovy pill in the U.S., with potential launches in selected international markets.

Strategic Acquisitions

Novo Nordisk announced acquisitions of Akero and Omeros' zaltenibart assets to strengthen their pipeline in diabetes and obesity.

Novo Nordisk (NVO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NVO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 04, 2026	2025 (Q4)	0.93 / -	0.886	―	―	―
Nov 05, 2025	2025 (Q3)	0.76 / 0.69	0.881	-21.45% (-0.19)
Aug 06, 2025	2025 (Q2)	0.92 / 0.93	0.658	41.19% (+0.27)
May 07, 2025	2025 (Q1)	0.92 / 0.99	0.814	22.24% (+0.18)
Feb 05, 2025	2024 (Q4)	0.83 / 0.89	0.716	23.74% (+0.17)
Nov 06, 2024	2024 (Q3)	0.88 / 0.88	0.711	23.91% (+0.17)
Aug 07, 2024	2024 (Q2)	0.71 / 0.66	0.638	3.13% (+0.02)
May 02, 2024	2024 (Q1)	0.75 / 0.81	0.648	25.62% (+0.17)	―
Jan 31, 2024	2023 (Q4)	0.67 / 0.72	0.432	65.74% (+0.28)	―
Nov 02, 2023	2023 (Q3)	0.68 / 0.71	0.42	69.29% (+0.29)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NVO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 05, 2025	$48.25	$48.46	+0.44%
Aug 06, 2025	$46.85	$45.02	-3.91%
May 07, 2025	$65.77	$67.02	+1.90%
Feb 05, 2025	$81.00	$84.05	+3.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.